Ochre Bio Company

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
Technology: Biopharma, Biotechnology, Health Care, Therapeutics
Industry: Early Drug Development, Preclinical Development, Regenerative medicine
Headquarters: Oxford, Oxfordshire, United Kingdom
Founded Date: 2019-09-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 10
Total Funding: 9750000
Estimated Revenue: Less than $1M
Last Funding Date: 2021-12-10
Last Funding Type: Series A

Visit Website
contact@ochre-bio.com
https://twitter.com/OchreBio
Register and Claim Ownership